BRPI0415771A - detecção de mutações em um gene associado à resistência a infecção viral, oas1 - Google Patents

detecção de mutações em um gene associado à resistência a infecção viral, oas1

Info

Publication number
BRPI0415771A
BRPI0415771A BRPI0415771-0A BRPI0415771A BRPI0415771A BR PI0415771 A BRPI0415771 A BR PI0415771A BR PI0415771 A BRPI0415771 A BR PI0415771A BR PI0415771 A BRPI0415771 A BR PI0415771A
Authority
BR
Brazil
Prior art keywords
oas1
resistance
gene
detection
viral infection
Prior art date
Application number
BRPI0415771-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Shawn P Iadonato
Charles L Magness
Gary Rosenburg
Christina A Scherer
Thierry Guillaudeux
Original Assignee
Illumigen Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36591413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0415771(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Illumigen Biosciences Inc filed Critical Illumigen Biosciences Inc
Publication of BRPI0415771A publication Critical patent/BRPI0415771A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
BRPI0415771-0A 2003-10-23 2004-10-22 detecção de mutações em um gene associado à resistência a infecção viral, oas1 BRPI0415771A (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US51388803P 2003-10-23 2003-10-23
US54237304P 2004-02-06 2004-02-06
US55475804P 2004-03-19 2004-03-19
US56052404P 2004-04-08 2004-04-08
US57832304P 2004-06-09 2004-06-09
US58350304P 2004-06-28 2004-06-28
US60524304P 2004-08-26 2004-08-26
PCT/US2004/035284 WO2005040428A2 (en) 2003-10-23 2004-10-22 Detection of mutations in a gene associated with resistance to viral infection, oas1

Publications (1)

Publication Number Publication Date
BRPI0415771A true BRPI0415771A (pt) 2006-12-26

Family

ID=36591413

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415771-0A BRPI0415771A (pt) 2003-10-23 2004-10-22 detecção de mutações em um gene associado à resistência a infecção viral, oas1

Country Status (9)

Country Link
US (8) US8192973B2 (https=)
EP (4) EP1689888A2 (https=)
JP (1) JP2007529199A (https=)
KR (1) KR20060116825A (https=)
CN (3) CN1910293B (https=)
AU (1) AU2004283294B2 (https=)
BR (1) BRPI0415771A (https=)
CA (1) CA2543789A1 (https=)
WO (1) WO2005040428A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1910293B (zh) 2003-10-23 2011-04-13 伊洛默格生物科学公司 检测与抗病毒感染性有关的基因oas1中的突变的方法
UA95446C2 (ru) 2005-05-04 2011-08-10 Іллюміджен Байосайєнсіз, Інк. Мутаци в генах oas1
TWI465460B (zh) 2005-11-23 2014-12-21 Kineta Two Llc 用於治療病毒感染及癌症之新穎醫藥組合物
US20080038753A1 (en) * 2006-08-01 2008-02-14 Illumigen Biosciences, Inc. Pharmaceutical manufacturing methods
EP2207902A1 (en) * 2007-11-09 2010-07-21 INSERM (Institut National de la Santé et de la Recherche Medicale) A method for predicting the therapeutic responsiveness of patients to a medical treatment with an interferon
EP2123748A1 (en) 2008-05-20 2009-11-25 Institut Pasteur 2'-5'-oligoadenylate synthetase 3 for preventing and treating positive-sense single-stranded rna virus infection
US20110104138A1 (en) 2009-11-03 2011-05-05 Institut Pasteur Use of the innate immunity gene oasl for preventing or treating infection with negative strand rna viruses
CN102517338B (zh) * 2011-12-09 2014-07-23 宁夏共享集团有限责任公司 一种微生物发酵糠醛渣生产生化腐植酸的方法
CN112585470A (zh) * 2018-06-21 2021-03-30 乌得勒支大学控股有限责任公司 用于监测样品中激酶活性的方法
CN117305441B (zh) * 2023-10-13 2025-04-08 福建农林大学 一种2型糖尿病的生物标志物和治疗靶点及浒苔寡糖的应用方法

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356270A (en) 1977-11-08 1982-10-26 Genentech, Inc. Recombinant DNA cloning vehicle
SE428332B (sv) 1979-03-08 1983-06-20 Wallac Oy Forfarande for fluorescensspektroskopisk bestemning av biologiskt aktivt emne, sasom hapten, antikropp eller antigen
US4293652A (en) 1979-05-25 1981-10-06 Cetus Corporation Method for synthesizing DNA sequentially
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
US4863873A (en) 1980-01-14 1989-09-05 Esa, Inc. Method for biological testing and/or developing pharmaceuticals for treatment of disorders
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
US4416988A (en) 1980-12-23 1983-11-22 Harvey Rubin Detection and isolation of enkephalin mRNA using a synthetic oligodeoxynucleotide
DE3207053A1 (de) 1982-02-26 1983-09-15 Esselte Pendaflex Corp., 11530 Garden City, N.Y. Etikettiergeraet
SE8301395L (sv) 1983-03-15 1984-09-16 Wallac Oy Kelatiserande foreningar med funktionella grupper vilka tillater kovalent koppling till bio-organiska molekyler
US4582789A (en) 1984-03-21 1986-04-15 Cetus Corporation Process for labeling nucleic acids using psoralen derivatives
US4617261A (en) 1984-03-21 1986-10-14 Cetus Corporation Process for labeling nucleic acids and hybridization probes
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4707404A (en) 1984-04-03 1987-11-17 Mitsubishi Paper Mills, Ltd. Thermal transfer recording material
JPS60222842A (ja) 1984-04-19 1985-11-07 Fuji Photo Film Co Ltd ハロゲン化銀写真乳剤およびその製造方法
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4965188A (en) 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
JP2509574B2 (ja) 1985-08-15 1996-06-19 アモコ・コーポレーション 標識付けした核酸
WO1987002708A1 (en) 1985-10-24 1987-05-07 Siska Diagnostics, Inc. Lanthanide chelate-tagged nucleic acid probes
US4946773A (en) 1985-12-23 1990-08-07 President And Fellows Of Harvard College Detection of base pair mismatches using RNAase A
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US4889818A (en) 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0260032B1 (en) 1986-09-08 1994-01-26 Ajinomoto Co., Inc. Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4863876A (en) 1987-01-15 1989-09-05 Hevey Richard C Method of detecting and quantifying ligands in liquids via biotin-avidin-medicated fluorescence polarization
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5403711A (en) 1987-11-30 1995-04-04 University Of Iowa Research Foundation Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
ATE151467T1 (de) 1987-11-30 1997-04-15 Univ Iowa Res Found Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene
US5254678A (en) 1987-12-15 1993-10-19 Gene Shears Pty. Limited Ribozymes
US5789214A (en) 1988-03-08 1998-08-04 Novartis Finance Corporation Method of inducing gene transcription in a plant
US5614395A (en) 1988-03-08 1997-03-25 Ciba-Geigy Corporation Chemically regulatable and anti-pathogenic DNA sequences and uses thereof
CA1340323C (en) 1988-09-20 1999-01-19 Arnold E. Hampel Rna catalyst for cleaving specific rna sequences
US5457183A (en) 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US5144019A (en) 1989-06-21 1992-09-01 City Of Hope Ribozyme cleavage of HIV-I RNA
US5272262A (en) 1989-06-21 1993-12-21 City Of Hope Method for the production of catalytic RNA in bacteria
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
NZ236819A (en) 1990-02-03 1993-07-27 Max Planck Gesellschaft Enzymatic cleavage of fusion proteins; fusion proteins; recombinant dna and pharmaceutical compositions
DE4039415A1 (de) 1990-02-03 1991-08-08 Boehringer Mannheim Gmbh Verfahren zur herstellung rekombinanter proteine ohne n-terminalen methioninrest
US5149797A (en) 1990-02-15 1992-09-22 The Worcester Foundation For Experimental Biology Method of site-specific alteration of rna and production of encoded polypeptides
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5180818A (en) 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
US5245022A (en) 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
US5639949A (en) 1990-08-20 1997-06-17 Ciba-Geigy Corporation Genes for the synthesis of antipathogenic substances
ES2260886T3 (es) 1990-11-23 2006-11-01 Bayer Bioscience N.V. Procedimiento para transformar plantas monocotiledoneas.
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US5700922A (en) 1991-12-24 1997-12-23 Isis Pharmaceuticals, Inc. PNA-DNA-PNA chimeric macromolecules
US5565552A (en) 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
US5266459A (en) 1992-02-24 1993-11-30 The Scripps Research Institute Gaucher's disease: detection of a new mutation in intron 2 of the glucocerebrosidase gene
US5593874A (en) 1992-03-19 1997-01-14 Monsanto Company Enhanced expression in plants
US5652355A (en) 1992-07-23 1997-07-29 Worcester Foundation For Experimental Biology Hybrid oligonucleotide phosphorothioates
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5866781A (en) 1993-03-08 1999-02-02 The Cleveland Clinic Foundation Antiviral transgenic plants, vectors, cells and methods
DE733059T1 (de) 1993-12-09 1997-08-28 Univ Jefferson Verbindungen und verfahren zur ortsspezifischen mutation in eukaryotischen zellen
US5597709A (en) 1994-01-27 1997-01-28 Human Genome Sciences, Inc. Human growth hormone splice variants hGHV-2(88) and hGHV-3(53)
BR9507425A (pt) 1994-02-18 1997-09-16 Cleveland Clinic Foundation Planta transgênica planta de tabaco transgênica vetor de transformaç o de planta célula de planta planta de tabaco diferenciada célula bacteriana planta de tabaco Processo para produzir geneticamente plantas transformadas construç o sequência de nucleotídeo isolada e sequência de aminoácido
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5597696A (en) 1994-07-18 1997-01-28 Becton Dickinson And Company Covalent cyanine dye oligonucleotide conjugates
US5514758A (en) 1994-09-30 1996-05-07 The Goodyear Tire & Rubber Company Process for making latex for high performance masking tape
US5480640A (en) 1995-05-02 1996-01-02 Schering Corporation Alpha interferon for treating prostate cancer
US5840565A (en) 1995-08-22 1998-11-24 The Regents Of The University Of California Methods for enhancing the production of viral vaccines in PKR-deficient cell culture
US5693512A (en) 1996-03-01 1997-12-02 The Ohio State Research Foundation Method for transforming plant tissue by sonication
NZ333802A (en) 1996-08-02 2001-09-28 Genesense Technologies Inc Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
AU9131698A (en) 1997-09-08 1999-03-29 Princeton University Human genes regulated by human cytomegalovirus and interferon
WO1999028447A1 (en) 1997-12-04 1999-06-10 Isis Pharmaceuticals, Inc. Human rnase h and compositions and uses thereof
US20030044783A1 (en) 2000-03-09 2003-03-06 Williams Lewis T. Human genes and gene expression products
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
EP0998579A1 (en) 1998-03-30 2000-05-10 ESA, Inc. Methodology for predicting and/or diagnosing disease
US5958773A (en) 1998-12-17 1999-09-28 Isis Pharmaceuticals Inc. Antisense modulation of AKT-1 expression
US20010034023A1 (en) 1999-04-26 2001-10-25 Stanton Vincent P. Gene sequence variations with utility in determining the treatment of disease, in genes relating to drug processing
US20030165921A1 (en) 2000-02-03 2003-09-04 Tang Y. Tom Novel nucleic acids and polypeptides
EP1261743A2 (en) * 2000-03-07 2002-12-04 Hyseq, Inc. Novel nucleic acids and polypeptides
AU2001251613A1 (en) * 2000-04-14 2001-10-30 Millennum Pharmaceuticals, Inc. Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
FR2823224B1 (fr) * 2001-04-04 2003-10-31 Pasteur Institut Utilisation de genes oas impliques dans la sensibilite/resistance a l'infection par les flaviviridae pour le criblage de molecules antivirales
DE10122206A1 (de) 2001-05-08 2002-11-28 Switch Biotech Ag Verwendung von Polypeptiden oder diese kodierende NukleInsäuren einer 2'-5'- Oligoadenylate Synthetase und/oder RNAseL zur Diagnose, Prävention oder Behandlung von Hauterkrankungen oder Wundheilung sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
WO2002090552A2 (en) 2001-05-08 2002-11-14 Switch Biotech Ag Use of 2'-5'-oligoadenylate synthetase and/or rnasel or nucleic acids encoding them for diagnosis, prophylaxis or treatment of wound healing
US6818420B2 (en) 2002-02-27 2004-11-16 Biosource International, Inc. Methods of using FET labeled oligonucleotides that include a 3′-5′ exonuclease resistant quencher domain and compositions for practicing the same
GB0208928D0 (en) * 2002-04-19 2002-05-29 Imp College Innovations Ltd Methods
WO2003092618A2 (en) * 2002-04-30 2003-11-13 University Of South Florida Materials and methods for prevention and treatment of rna viral diseases
AU2003299505A1 (en) 2002-05-17 2004-06-03 Baylor College Of Medicine Identification of oligoadenylate synthetase-like genes
AU2003248723A1 (en) * 2002-06-19 2004-01-06 Georgia State University Research Foundation, Inc. Compositions and methods for viral resistance genes
BR0311527A (pt) 2002-06-20 2005-02-22 Unilever Nv Processo para preparação de composição detergente sólida não-granular com bolhas de gás aprisionadas
US20050191649A1 (en) 2003-10-23 2005-09-01 Illumigen Biosciences, Inc. Detection of mutations in a gene associated with resistance to viral infection, OAS1
CN1910293B (zh) 2003-10-23 2011-04-13 伊洛默格生物科学公司 检测与抗病毒感染性有关的基因oas1中的突变的方法
UA95446C2 (ru) 2005-05-04 2011-08-10 Іллюміджен Байосайєнсіз, Інк. Мутаци в генах oas1
DE102006036763A1 (de) 2006-08-05 2008-02-07 Khs Ag Vorrichtung und Verfahren zur Sterilisation von Behältern

Also Published As

Publication number Publication date
AU2004283294A1 (en) 2005-05-06
US20110237501A1 (en) 2011-09-29
US20120321608A1 (en) 2012-12-20
CN1910293B (zh) 2011-04-13
JP2007529199A (ja) 2007-10-25
CN102174538A (zh) 2011-09-07
EP1689888A2 (en) 2006-08-16
US20090123472A1 (en) 2009-05-14
KR20060116825A (ko) 2006-11-15
WO2005040428A3 (en) 2005-09-15
US20070154467A1 (en) 2007-07-05
EP2267154A1 (en) 2010-12-29
EP2305798A3 (en) 2011-04-20
EP2305798A2 (en) 2011-04-06
US20120253027A1 (en) 2012-10-04
AU2004283294B2 (en) 2011-03-17
WO2005040428A2 (en) 2005-05-06
US8551772B2 (en) 2013-10-08
US20140037717A1 (en) 2014-02-06
US8192973B2 (en) 2012-06-05
CN103495153A (zh) 2014-01-08
US9090947B2 (en) 2015-07-28
EP2083089A1 (en) 2009-07-29
US20110071073A1 (en) 2011-03-24
US8088907B2 (en) 2012-01-03
CN1910293A (zh) 2007-02-07
HK1161740A1 (en) 2012-08-03
US20140010800A1 (en) 2014-01-09
CA2543789A1 (en) 2005-05-06
CN102174538B (zh) 2013-06-19

Similar Documents

Publication Publication Date Title
WO2005059108A3 (en) Gene expression profiles and methods of use
WO2002058638A3 (en) Serpin drugs for treatment of hiv infection and method of use thereof
EP2037737A4 (en) PROTEINS, NUCLEIC ACIDS FOR THEIR CODING AND CORRESPONDING USES.
WO2004066941A3 (en) Expression profiles for colon cancer and methods of use
NZ593289A (en) Anti-neuropilin-1 antibodies for treating angiogenesis
WO2005032495A3 (en) Gene expression profiles and methods of use
BRPI0415771A (pt) detecção de mutações em um gene associado à resistência a infecção viral, oas1
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
IL171356A (en) Anti-interferon receptor antibody for treatment of inflammatory bowel disease
NO20050134D0 (no) Difenylazetidioner substituert med syregrupper, fremgangsmate for fremstilling av disse, medikamenter inneholdende disse forbindelser og deres anvendelse
WO2008073177A3 (en) Expression profiles associated with irinotecan treatment
WO2004078035A3 (en) Expression profiles for breast cancer and methods of use
WO2004047767A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2004044164A3 (en) Method for identifying risk of melanoma and treatments thereof
WO2004094476A3 (en) Compositions and methods relating to stop-1
WO2005014846A3 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2004081043A3 (en) Baff mutants with at least one amino acid substitution and methods of their production
Gupta et al. Interleukin‐28b CC genotype predicts early treatment response and CT/TT genotypes predicts non‐response in patients infected with HCV genotype 3
WO2003093492A3 (en) Compositions and methods for determining susceptibility of hepatitis c virus to anti-viral drugs
WO2007058968A3 (en) Gene expression profiles and methods of use
DK1689886T3 (da) Molekylær markör associeret med CMV-resistens og anvendelse deraf
WO2006022619A3 (en) Methods for identifying risk of type ii diabetes and treatments thereof
TW200734638A (en) Method for the diagnosis of thromboembolic and coronary heart diseases
BRPI0409557B8 (pt) proteína recombinante inibidora de calicreína, sequência de dna, vetor de expressão, composição farmacêutica, uso da composição farmacêutica, método de produção da proteína recombinanete e kits de diagnóstico
NZ591879A (en) Detection of mutations in a gene associated with resistance to viral infection, OAS1

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: ILLUMIGEN BIOSCIENCES, INC. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020080150457/RJ DE 05/12/2008.

B25G Requested change of headquarter approved

Owner name: ILLUMIGEN BIOSCIENCES, INC. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020080150457/RJ DE 05/12/2008.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6AANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE 8.6 DA RPI 2112 DE 28/06/2011.